News – March 2023 AIM™ service (Annogen Integration Mapping: integration sites and their expression levels) was introduced in 2022 supporting cell engineering for cell therapy development. Now it is also available to the contract manufacturing market: manufacturing...

PRESS RELEASE The Netherlands, 26 January 2023 Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with another top agricultural science and technology...

PRESS RELEASE Amsterdam, The Netherlands, 19 January 2023 Annogen to develop multiple CNS-cell specific promoters for VectorY programs VectorY Therapeutics, a biotech company developing innovative vectorized antibody approaches for the treatment of neurodegenerative...

PRESS RELEASE Amsterdam, 13 December 2022 Annogen will functionally annotate tens of thousands of disease-related non-coding sequence variants with the goal of aiding drug discovery Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the...

Identify favorable gene insertions and their expression levels (> 100,000 integrations in parallel) Annogen introduces a new service to identify gene insertions and asses their expression levels for >100,000 integrations in parallel. Using an adaptation of its...

Researchers aim to pinpoint non-gene components in DNA linked to production and welfare traits in cattle, gaining insights across species. Researchers are developing a method of identifying specific letters in the DNA code that govern the development of key physical...

Many diseases are determined by differences in yet undiscovered gene regulation. Thanks to plasmids and 'barcodes', the SuRE assay can map this relatively easily and extensively for the entire human genome. 'The breakthrough came from the idea of using barcodes,' says...

PRESS RELEASE Amsterdam, 30 November 2021 Under the agreement Annogen will use its proprietary SuRE™ technology to generate genome-wide regulatory profiles to identify disease-relevant regulatory activity and disease-relevant non-coding sequence variants. Annogen...

Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with a Tier 1 agricultural firm to identify non-coding DNA fragments in plants’ genomes that influence...